Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 344 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | October 16, 2014

AbbVie Inc to Shire: It's Not You, It's My Country

AbbVie's board recommends that the company not purchase Shire.

Investing | October 10, 2014

Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery

Amgen is developing a biosimilar of AbbVie's Humira.

Dividends & Income Investing | October 06, 2014

Better Dividend Stock: Amgen, Inc. or AbbVie Inc.?

Investing in dividend stocks might appear easy, but not all dividends are really pulling their weight. After biopharmaceutical giants Amgen and AbbVie face off, find out which company is really the better dividend stock for investors.

Investing | October 02, 2014

Why Allergan Inc. Is an Activist Investor Target

Botox-maker Allergan has attracted activist investors in droves lately. Here's why.

Investing | September 19, 2014

3 Biotechs Investors Should Watch

The healthcare version of Where the Money Is.

Investing | September 02, 2014

3 Reasons Eli Lilly & Co.'s Stock Could Rise

With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?

Investing | August 26, 2014

3 Reasons Celgene Corporation's Stock Could Fall

Celgene shares are up more than 1,200% over the past decade. But these three headwinds could be the brick wall that sends its stock lower.

Investing | August 15, 2014

Why Achillion Pharmaceuticals, Inc. Stock Soared

Achillion stock is among the top gainers as its experimental hepatitis C combination therapy delivers "perfect" results.

Investing | July 19, 2014

This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results

A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.

Investing | July 16, 2014

Will Incoming Competition Derail Aegerion Stock?

A new class of cholesterol drugs including Amgen's (AMGN) evolocumab could soon be competing for Aegerion's (AEGR) market share in HoFH patients.

Results 1 - 10 of 344 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology